Vasculitis associated with VEXAS syndrome

Megan M. Sullivan(Mayo Clinic in Arizona), Matthew J. Koster(Mayo Clinic in Arizona), Julio C. Sartori‐Valinotti(Mayo Clinic in Arizona), Horatiu Olteanu(Mayo Clinic in Arizona), Ronald S. Go(Mayo Clinic), Carolyn Mead‐Harvey(Mayo Clinic in Arizona), Alexander Hines(WinnMed), Kenneth J. Warrington(Mayo Clinic), Melanie C. Bois(Mayo Clinic in Arizona), Yael Kusne(WinnMed), Mrinal M. Patnaik(Mayo Clinic), Kaaren K. Reichard(Mayo Clinic), Daniel Montes(WinnMed), Kambiz Kalantari(Mayo Clinic), Abhishek A. Mangaonkar(Mayo Clinic)

Lara D. Veeken

October 11, 2024

10.1093/rheumatology/keae550

Cited by 26

Related Papers

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

|The Lancet|2008|862

Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin

|Journal of Clinical Oncology|1999|697

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

|Journal of Clinical Oncology|2012|682

Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years

|Journal of Oncology Practice|2017|447